secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kyverna Therapeutics, Inc. (KYTX)
CIK:        0001994702
Form:       8-K
Filed at:   2026-05-12T20:05:31+00:00
Accession:  0001193125-26-219377
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kyverna reports Q1 net loss $39.7M; initiates rolling BLA for miv-cel in SPS
----------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities of $236.4M as of March 31, 2026; cash runway expected into 2028.
- Net loss of $39.7M ($0.66 per share) for Q1 2026; R&D expenses $30.1M, G&A $11.3M.
- Initiated rolling BLA submission for miv-cel in stiff person syndrome after positive pre-BLA meeting with FDA; completion expected Q4 2026.
- Primary analysis of KYSA-8 trial in SPS showed statistically significant durable benefit across all endpoints; 100% of patients free of immunotherapies at week 16.
- Appointed Nadia Dac as Chief Commercial Officer; enrollment ongoing in Phase 3 gMG trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1994702/000119312526219377/0001193125-26-219377-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1994702/000119312526219377/kytx-20260512.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-219377

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer